Cargando…
Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?
Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and i...
Autores principales: | Zulzaga, Zuzaan, Myagmarsuren, Erdenetuya, Woerdenbag, Herman J., van Puijenbroek, Eugene P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938544/ https://www.ncbi.nlm.nih.gov/pubmed/33678195 http://dx.doi.org/10.1186/s40545-021-00298-8 |
Ejemplares similares
-
How far are we from viral hepatitis elimination service coverage targets?
por: Hutin, Yvan J‐F, et al.
Publicado: (2018) -
Innovations in tuberculosis diagnostics: How far are we from reaching our goal?
por: Varma-Basil, Mandira, et al.
Publicado: (2019) -
Registration, Evaluation, and Authorization of Chemicals (REACH) Is but the First Step–How Far Will It Take Us? Six Further Steps to Improve the European Chemicals Legislation
por: Rudén, Christina, et al.
Publicado: (2010) -
Sixth Africa malaria day in 2006: how far have we come after the Abuja Declaration?
por: Rugemalila, Joas B, et al.
Publicado: (2006) -
Cost-Effective Pharmacologic Therapies to Treat Chronic Hepatitis B: How Far Have We Really Come?
por: Holbrook, Michelle
Publicado: (2008)